Holen Sie sich die Stockscreener-App
4.15
242.98%
2.94
Handel nachbörslich:
3.84
-0.31
-7.47%
Schlusskurs vom Vortag:
$1.21
Offen:
$1.3
24-Stunden-Volumen:
128.54M
Relative Volume:
3,240.86
Marktkapitalisierung:
$3.70M
Einnahmen:
$129.20K
Nettoeinkommen (Verlust:
$-7.44M
KGV:
-0.3709
EPS:
-11.19
Netto-Cashflow:
$-8.62M
1W Leistung:
+267.26%
1M Leistung:
+254.70%
6M Leistung:
+159.38%
1J Leistung:
-41.05%
1-Tages-Spanne:
$1.30
$4.40
1-Wochen-Bereich:
$1.105
$4.40
52-Wochen-Spanne:
$1.08
$10.02
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Firmenname
Sonnet Biotherapeutics Holdings Inc
Sektor
Branche
Telefon
609-375-2227
Adresse
100 OVERLOOK CENTER, PRINCETON, NJ
Vergleichen Sie SONN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
4.15 | 3.70M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sonnet Biotherapeutics Holdings Inc Aktie (SONN) Neueste Nachrichten
Two Sigma Investments LP Invests $28,000 in Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) - Defense World
Reviewing Sonnet BioTherapeutics (NASDAQ:SONN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
sonnet biotherapeutics receives nasdaq delisting notice By Investing.com - Investing.com South Africa
sonnet biotherapeutics receives nasdaq delisting notice - Investing.com
Sonnet BioTherapeutics Faces Nasdaq Non-Compliance Notice - TipRanks
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Price Up 5.3% – What’s Next? - Defense World
SONN stock touches 52-week low at $1.1 amid market challenges - Investing.com Australia
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sonnet BioTherapeutics Holdings, Inc. SEC 10-Q Report - TradingView
Sonnet BioTherapeutics (SONN) Expected to Announce Earnings on Tuesday - Defense World
Sonnet Chief Medical Officer, Richard Kenney, M.D., to - GlobeNewswire
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit - The Globe and Mail
Chanticleer Holdings Little Big Burger Partner and Brand Ambassador Denny Hamlin Wins the Daytona 500 - marketscreener.com
Sonnet Releases Virtual Investor "What This Means" Segment | SONN Stock News - GuruFocus
Sonnet BioTherapeutics Discusses Positive Safety Data for SON-1010 in Virtual Investor Segment - Nasdaq
Sonnet Releases Virtual Investor "What This Means" Segment - GlobeNewswire
Biotech Leader Dr. Pankaj Mohan Honored on NASDAQ After Tragic Crash - newsindiatimes.com
Sonnet BioTherapeutics (NASDAQ:SONN) Receives Buy Rating from Chardan Capital - Defense World
SONN stock touches 52-week low at $1.18 amid market challenges - Investing.com India
Sonnet BioTherapeutics reports positive results from ovarian cancer therapy trial - Yahoo Finance
Sonnet BioTherapeutics advances in cancer trial - Investing.com Australia
Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up - MarketScreener
Sonnet BioTherapeutics advances in cancer trial By Investing.com - Investing.com South Africa
Sonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab combo - TipRanks
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - The Manila Times
Sonnet'S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer - MarketScreener
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in - GlobeNewswire
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - GlobeNewswire
Sonnet BioTherapeutics appoints interim CEO and new president By Investing.com - Investing.com Canada
Sonnet Announces Release of Corporate Update Video - GlobeNewswire
Sonnet BioTherapeutics appoints interim CEO and new president - Investing.com
Sonnet BioTherapeutics Announces New Interim CEO Appointment - TipRanks
Pilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech Company - NewsBreak: Local News & Alerts
Pilot killed in N.J. plane crash was biotech company founder, CEO - NJ.com
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - citybiz
Sonnet BioTherapeutics appoints interim CEO after founder’s death - Investing.com
Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan - marketscreener.com
Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World
Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter
SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia
Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire
Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener
Finanzdaten der Sonnet Biotherapeutics Holdings Inc-Aktie (SONN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):